O	0	6	Effect
O	7	9	of
B-intervention	10	14	oral
I-intervention	15	25	clodronate
O	26	28	on
B-condition	29	33	bone
I-condition	34	38	mass
I-condition	38	39	,
I-condition	40	44	bone
I-condition	45	53	turnover
I-condition	54	57	and
I-condition	58	68	subsequent
I-condition	69	79	metastases
O	80	82	in
O	83	88	women
O	89	93	with
O	94	101	primary
O	102	108	breast
O	109	115	cancer
O	115	116	.

O	117	123	Breast
O	124	130	cancer
O	131	141	treatments
O	142	146	have
O	147	151	been
O	152	162	associated
O	163	167	with
O	168	179	accelerated
O	180	184	bone
O	185	189	loss
O	190	193	and
O	194	203	increased
O	204	216	osteoporosis
O	217	221	risk
O	221	222	.

O	223	225	In
O	226	227	a
O	228	236	subgroup
O	237	245	analysis
O	246	248	of
O	249	250	a
O	251	261	randomised
O	261	262	,
O	263	269	double
O	269	270	-
O	270	275	blind
O	275	276	,
O	277	284	placebo
O	284	285	-
O	285	295	controlled
O	296	301	study
O	301	302	,
O	303	305	we
O	306	314	compared
O	315	318	the
O	319	326	changes
O	327	329	in
O	330	335	spine
O	336	339	and
O	340	345	total
O	346	349	hip
O	350	354	bone
O	355	362	mineral
O	363	370	density
O	371	372	(
O	372	375	BMD
O	375	376	)
O	377	380	and
O	381	392	biochemical
O	393	400	markers
O	401	403	of
O	404	408	bone
O	409	417	turnover
O	418	420	in
B-eligibility	421	426	women
I-eligibility	427	431	with
I-eligibility	432	439	primary
I-eligibility	440	446	breast
I-eligibility	447	453	cancer
O	454	457	who
O	458	461	had
O	462	470	received
O	471	479	standard
O	480	487	therapy
O	488	492	plus
O	493	499	either
O	500	504	oral
O	505	515	clodronate
O	516	520	1600
O	521	523	mg
O	523	524	/
O	524	525	d
O	526	527	(
O	527	528	n
O	528	529	=
B-intervention-participants	529	532	419
O	532	533	)
O	534	536	or
B-control	537	544	placebo
O	545	546	(
O	546	547	n
O	547	548	=
B-control-participants	548	551	432
O	551	552	)
O	553	556	for
O	557	558	2
O	559	564	years
O	564	565	.

O	566	571	After
O	572	573	2
O	574	579	years
O	579	580	,
B-outcome	581	586	spine
I-outcome	587	590	BMD
O	591	594	was
O	595	596	1
O	596	597	.
O	597	599	92
O	599	600	%
O	601	607	higher
O	608	610	in
O	611	619	patients
O	620	623	who
O	624	632	received
O	633	643	clodronate
O	644	651	instead
O	652	654	of
O	655	662	placebo
O	663	664	(
O	664	665	P
O	665	666	<
O	666	667	0
O	667	668	.
O	668	672	0001
O	672	673	)
O	674	677	and
B-outcome	678	683	total
I-outcome	684	687	hip
I-outcome	688	691	BMD
O	692	695	was
O	696	697	1
O	697	698	.
O	698	700	29
O	700	701	%
O	702	708	higher
O	709	710	(
O	710	711	P
O	711	712	=
O	712	713	0
O	713	714	.
O	714	717	002
O	718	724	versus
O	725	732	placebo
O	732	733	)
O	733	734	.

O	735	743	Patients
O	744	747	who
O	748	756	received
O	757	767	clodronate
O	768	771	had
O	772	773	a
O	774	780	median
O	781	783	26
O	783	784	%
O	785	794	reduction
O	795	797	in
B-outcome	798	804	levels
I-outcome	805	807	of
I-outcome	808	813	serum
I-outcome	814	815	N
I-outcome	815	816	-
I-outcome	816	824	terminal
I-outcome	825	828	pro
I-outcome	828	829	-
I-outcome	829	836	peptide
I-outcome	837	839	of
I-outcome	840	844	type
I-outcome	845	846	I
I-outcome	847	858	procollagen
I-outcome	859	860	(
I-outcome	860	864	PINP
I-outcome	864	865	)
I-outcome	865	866	-
O	866	867	-
O	867	868	a
O	869	875	marker
O	876	878	of
O	879	883	bone
O	884	892	turnover
O	892	893	-
O	893	894	-
O	894	899	after
O	900	901	2
O	902	907	years
O	908	910	of
O	911	918	therapy
O	918	919	.

O	920	924	This
O	925	933	compares
O	934	938	with
O	939	940	a
O	941	947	median
O	948	949	5
O	949	950	%
O	951	959	increase
O	960	962	in
O	963	971	patients
O	972	975	who
O	976	984	received
O	985	992	placebo
O	993	994	(
O	994	995	P
O	995	996	<
O	996	997	0
O	997	998	.
O	998	1002	0001
O	1002	1003	)
O	1003	1004	.

O	1005	1012	Effects
O	1013	1015	on
O	1016	1019	BMD
O	1019	1020	,
O	1021	1024	but
O	1025	1028	not
O	1029	1040	biochemical
O	1041	1048	markers
O	1048	1049	,
O	1050	1059	persisted
O	1060	1063	for
O	1064	1066	up
O	1067	1069	to
O	1070	1071	3
O	1072	1077	years
O	1078	1082	post
O	1082	1083	-
O	1083	1092	treatment
O	1092	1093	.

O	1094	1099	Early
O	1100	1107	changes
O	1108	1110	in
O	1111	1115	PINP
O	1116	1120	were
O	1121	1131	associated
O	1132	1136	with
O	1137	1144	changes
O	1145	1147	in
O	1148	1151	BMD
O	1152	1155	and
O	1156	1159	the
O	1160	1170	likelihood
O	1171	1173	of
O	1174	1184	developing
O	1185	1189	bone
O	1190	1200	metastases
O	1200	1201	.

O	1202	1206	This
O	1207	1212	study
O	1213	1218	shows
O	1219	1222	the
O	1223	1226	use
O	1227	1229	of
O	1230	1234	oral
O	1235	1245	clodronate
O	1246	1252	during
O	1253	1260	primary
O	1261	1267	breast
O	1268	1274	cancer
O	1275	1284	treatment
O	1285	1287	is
O	1288	1298	associated
O	1299	1303	with
O	1304	1311	reduced
O	1312	1316	bone
O	1317	1325	turnover
O	1326	1329	and
O	1330	1340	protection
O	1341	1348	against
O	1349	1353	bone
O	1354	1364	metastases
O	1364	1365	.
